









Markets
/
Stocks
/
nasdaq-clym
/

Climb Bio Inc

CLYM

1.950USD

+0.030+1.56%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

132.14MMarket Cap

LossP/E TTM



Climb Bio Inc

1.950

+0.030+1.56%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Climb Bio Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Climb Bio Inc's Score

Industry at a Glance

Industry Ranking

206 / 501

Overall Ranking

362 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

9.200

Target Price

+379.17%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Climb Bio Inc Highlights

StrengthsRisks

Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -111.94, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 55.41M shares, decreasing 14.31% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 2.54K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.60.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Climb Bio Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 7.27, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -111.94, which is -99.43% below the recent high of -0.63 and -18.10% above the recent low of -132.20.

Score

Industry at a Glance

Previous score

7.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 206/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Climb Bio Inc is 9.00, with a high of 10.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

10.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

9.200

Target Price

+379.17%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Climb Bio Inc

CLYM

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 7.21, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.53 and the support level at 1.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.93

Change

0.28

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.021

Sell

RSI(14)

47.064

Neutral

STOCH(KDJ)(9,3,3)

24.149

Neutral

ATR(14)

0.184

Low Volatility

CCI(14)

-104.950

Sell

Williams %R

83.871

Oversold

TRIX(12,20)

-0.055

Sell

StochRSI(14)

48.938

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.960

Sell

MA10

2.004

Sell

MA20

2.008

Sell

MA50

2.096

Sell

MA100

1.832

Buy

MA200

1.603

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 81.77%, representing a quarter-over-quarter decrease of 11.67%. The largest institutional shareholder is The Vanguard, holding a total of 1.33M shares, representing 1.96% of shares outstanding, with 12.28% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

31.42M

Pontifax Venture Capital

5.21M

Cantor Fitzgerald, L.P

2.50M

+25.16%

Citi Investment Research (US)

1.61M

-12.88%

Affinity Asset Advisors LLC

1.50M

The Vanguard Group, Inc.

Star Investors

1.33M

-11.40%

Deep Track Capital LP

1.04M

Kynam Capital Management LP

1.03M

-1.78%

Tang Capital Management, LLC

1.00M

BlackRock Institutional Trust Company, N.A.

829.63K

-60.45%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -0.06. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.